The FDA approved Gilead Sciences' Bixlenvo, a new once-daily single tablet regimen for virologic

Archer Investment Corp acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) in

BNP Paribas boosted its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 20.7% during t

Beacon Pointe Advisors LLC decreased its position in shares of Gilead Sciences, Inc. (NASDAQ: GILD)

https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidem

GILD wins FDA approval for Bixlenvo, a once-daily HIV regimen offering a smaller single-tablet optio

Bamco Inc. NY reduced its holdings in shares of Gilead Sciences, Inc. (NASDAQ: GILD) by 40.0% in the

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the U.S. Food and Drug Administration (FDA)

The U.S. ​Food and ‌Drug Administration has ​approved ​Gilead Sciences' once ⁠daily ​oral combinatio

The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today t

Since earnings, investors have focused mainly on the biotech company's growth potential with its HIV

Trodelvy's latest EU approval with Keytruda expands its first-line metastatic TNBC use, strengthenin

These healthcare leaders are unlikely to suspend their dividend programs.

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 5 years by 4.4% on an annual

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the European Commission (EC) has granted ma

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the

Advisors Capital Management LLC bought a new position in Gilead Sciences, Inc. (NASDAQ: GILD) during

Allworth Financial LP bought a new stake in shares of Gilead Sciences, Inc. (NASDAQ: GILD) in the se

VanEck's concentrated 25-stock biotech play offers higher volatility, while iShares' broader pharma

Abacus FCF Advisors LLC bought a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) during the second

San Diego, California--(Newsfile Corp. - August 19, 2026) - Robbins LLP reminds investors that a sec

These stocks can be safe-haven investments to hide out in amid market turmoil.

Aljian Capital Management LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ: GILD) during th

Joshua Brown chose Snowflake Inc., while Rob Sechan picked KLA Corp and Brian Belski recommended Gil

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.04% on an annu

MacroGenics, Inc. (NASDAQ:MGNX), a clinical-stage biopharmaceutical company focused on developing in

Kathy Hochul says Trump's Medicare subsidy decision will raise prescription drug costs for 1.3 m

RBC Capital analyst Brian Abrahams maintains Gilead Sciences (NASDAQ:GILD) with a Sector Perform

Cantor Fitzgerald analyst Carter Gould reiterates Gilead Sciences (NASDAQ:GILD) with a Overweight

Needham analyst Joseph Stringer reiterates Gilead Sciences (NASDAQ:GILD) with a Buy and maintains

Gilead Sciences (NASDAQ:GILD) lowers FY2026 GAAP EPS guidance from $(3.25)-$(2.85) to $(3.75)-$(3.40

Gilead Sciences (NASDAQ:GILD) raises FY2026 Adj EPS guidance from $(1.05)-$(0.65) to $(0.65)-$(0.30)

Gilead Sciences (NASDAQ:GILD) reported quarterly losses of $(6.75) per share which beat the analyst

Earnings set for tight window on Tuesday, Benzinga Pro data show options pricing 3.19% move for Pfiz

California's highest court on Monday ruled in favor of Gilead Sciences GILD.O, in a case address

Earnings season is approaching, and Benzinga Pro has a list of top stocks to watch. Gilead Sciences

Barclays analyst Emily Field maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and lowe

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

Atea Pharmaceuticals announced positive Phase 3 C-BEYOND trial results for its oral hepatitis C comb

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Overweight

Gilead Sciences, Inc. (NASDAQ:GILD) today announced that the Committee for Medicinal Products for Hu

Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up t

Gilead & Merck Phase 3 data shows once-weekly ISL/LEN matches daily HIV meds in viral suppressio

Leerink Partners analyst Daina Graybosch downgrades Gilead Sciences (NASDAQ:GILD) from Outperform

Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 20 years by 2.19% on an annu

Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as cri